| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anne-Laure Cavin, Anne-Emmanuelle Hay, Andrew Marston, Helen Stoeckli-Evans, Rosario Scopelliti, Drissa Diallo, Kurt Hostettman. Bioactive diterpenes from the fruits of Detarium microcarpum. Journal of natural products. vol 69. issue 5. 2006-07-13. PMID:16724838. |
a fruit pulp extract of detarium microcarpum showed inhibition of the growth of the plant pathogenic fungus cladosporium cucumerinum and of the enzyme acetylcholinesterase, implicated in alzheimer's disease. |
2006-07-13 |
2023-08-12 |
Not clear |
| Marcella Reale, Carla Iarlori, Francesco Gambi, Claudio Feliciani, Lucci Isabella, Domenico Gamb. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology. vol 50. issue 5. 2006-07-06. PMID:16445950. |
the acetylcholinesterase inhibitor, donepezil, regulates a th2 bias in alzheimer's disease patients. |
2006-07-06 |
2023-08-12 |
human |
| Roger Bulloc. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer disease and associated disorders. vol 20. issue 1. 2006-07-03. PMID:16493232. |
efficacy was demonstrated in patients with newly diagnosed alzheimer disease, patients previously or currently receiving acetylcholinesterase inhibitors, and both institutionalized and community-dwelling alzheimer disease patients. |
2006-07-03 |
2023-08-12 |
Not clear |
| N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, G M Constantine, Ch A Mathis, J G Davis, R Y Moore, S T Dekosk. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. Journal of neurology. vol 253. issue 2. 2006-06-28. PMID:16133720. |
we recently reported findings that loss of cortical acetylcholinesterase (ache) activity is greater in parkinsonian dementia than in alzheimer's disease (ad). |
2006-06-28 |
2023-08-12 |
human |
| Sang-Yoon Lee, Yearn Seong Choe, Eun Kyoung Ryu, Yoichi Iimura, Yong Choi, Kyung-Han Lee, Byung-Tae Ki. Is subnanomolar binding affinity required for the in vivo imaging of acetylcholinesterase? Studies on 18F-labeled G379. Nuclear medicine and biology. vol 33. issue 1. 2006-06-19. PMID:16459263. |
acetylcholinesterase (ache) is an important cholinergic marker of alzheimer's disease (ad) and shows reduced activity in postmortem ad brain tissues. |
2006-06-19 |
2023-08-12 |
mouse |
| Martin R Farlow, Mary L Lill. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC geriatrics. vol 5. 2006-06-14. PMID:15659242. |
rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of alzheimer's disease (ad). |
2006-06-14 |
2023-08-12 |
Not clear |
| P Szymański, E Zurek, E Mikiciuk-Olasi. New tacrine-hydrazinonicotinamide hybrids as acetylcholinesterase inhibitors of potential interest for the early diagnostics of Alzheimer's disease. Die Pharmazie. vol 61. issue 4. 2006-05-30. PMID:16649535. |
new tacrine-hydrazinonicotinamide hybrids as acetylcholinesterase inhibitors of potential interest for the early diagnostics of alzheimer's disease. |
2006-05-30 |
2023-08-12 |
Not clear |
| P Szymański, E Zurek, E Mikiciuk-Olasi. New tacrine-hydrazinonicotinamide hybrids as acetylcholinesterase inhibitors of potential interest for the early diagnostics of Alzheimer's disease. Die Pharmazie. vol 61. issue 4. 2006-05-30. PMID:16649535. |
alzheimer disease (ad) is characterised by a deficit of acetylcholinesterase, and these new compounds, as ligands for 99mtc complexes, are potential radiopharmaceuticals for an early diagnosis of alzheimer's disease. |
2006-05-30 |
2023-08-12 |
Not clear |
| S Sener, M Ozsara. Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emergency medicine journal : EMJ. vol 23. issue 1. 2006-05-02. PMID:16373816. |
rivastigmine, which has been approved by the us food and drugs administration for the treatment of alzheimer's disease, is a non-competitive reversible inhibitor of acetylcholinesterase. |
2006-05-02 |
2023-08-12 |
Not clear |
| David P Elliott, Wayne L Atkinso. Use of the cognitive performance scale to identify under- and over-treatment of cognitive deficits in nursing home residents with dementia. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. vol 18. issue 4. 2006-04-25. PMID:16563060. |
to determine the practicality of using the minimum data set (mds) cognitive performance scale (cps) to evaluate the appropriateness of acetylcholinesterase inhibitor (achei) use in the treatment of alzheimer's disease and related disorders. |
2006-04-25 |
2023-08-12 |
Not clear |
| Urmila Thatt. Phenserine Axonyx. Current opinion in investigational drugs (London, England : 2000). vol 6. issue 7. 2006-04-18. PMID:16044670. |
the acetylcholinesterase inhibitor phenserine, the (-)-enantiomer of a phenylcarbamate derivative of physostigmine, is being developed as a potential therapy for alzheimer's disease by axonyx, under license from the national institutes of health/national institute on aging. |
2006-04-18 |
2023-08-12 |
Not clear |
| David H Smal. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert opinion on emerging drugs. vol 10. issue 4. 2006-04-14. PMID:16262564. |
acetylcholinesterase inhibitors for the treatment of dementia in alzheimer's disease: do we need new inhibitors? |
2006-04-14 |
2023-08-12 |
Not clear |
| David H Smal. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert opinion on emerging drugs. vol 10. issue 4. 2006-04-14. PMID:16262564. |
acetylcholinesterase inhibitors (acheis) have been shown to produce a small, but significant, improvement in cognition in patients with alzheimer's disease. |
2006-04-14 |
2023-08-12 |
Not clear |
| Soichiro Shimizu, Haruo Hanyu, Toshihiko Iwamoto, Kiyoshi Koizumi, Kimihiko Ab. SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease. Journal of neuroimaging : official journal of the American Society of Neuroimaging. vol 16. issue 1. 2006-04-11. PMID:16483272. |
treatment with acetylcholinesterase inhibitors (acheis) is beneficial for patients with alzheimer's disease (ad). |
2006-04-11 |
2023-08-12 |
Not clear |
| J Muñoz-Muriedas, J M Lopez, Modesto Orozco, F Javier Luqu. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease. Current pharmaceutical design. vol 10. issue 25. 2006-04-10. PMID:15544503. |
molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of alzheimer's disease. |
2006-04-10 |
2023-08-12 |
Not clear |
| J Muñoz-Muriedas, J M Lopez, Modesto Orozco, F Javier Luqu. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease. Current pharmaceutical design. vol 10. issue 25. 2006-04-10. PMID:15544503. |
the interest for acetylcholinesterase as a target for the palliative treatment of alzheimer's disease has been renewed in the last years owing to the evidences that support the role of this enzyme in accelerating the aggregation and deposition of the beta-amyloid peptide. |
2006-04-10 |
2023-08-12 |
Not clear |
| Da-Ming Du, Paul R Carlie. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. Current pharmaceutical design. vol 10. issue 25. 2006-04-10. PMID:15544504. |
development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for alzheimer's disease. |
2006-04-10 |
2023-08-12 |
Not clear |
| Da-Ming Du, Paul R Carlie. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. Current pharmaceutical design. vol 10. issue 25. 2006-04-10. PMID:15544504. |
at present the only fda-approved therapy for alzheimer's disease involves the administration of acetylcholinesterase inhibitors, to alleviate the cholinergic deficit associated with this disease. |
2006-04-10 |
2023-08-12 |
Not clear |
| Maurizio Recanatini, Piero Valent. Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics. Current pharmaceutical design. vol 10. issue 25. 2006-04-10. PMID:15544505. |
acetylcholinesterase inhibitors as a starting point towards improved alzheimer's disease therapeutics. |
2006-04-10 |
2023-08-12 |
Not clear |
| Hongxin Dong, Cynthia A Csernansky, Maureen V Martin, Amy Bertchume, Dana Vallera, John G Csernansk. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology. vol 181. issue 1. 2006-04-10. PMID:15778881. |
acetylcholinesterase inhibitors ameliorate behavioral deficits in the tg2576 mouse model of alzheimer's disease. |
2006-04-10 |
2023-08-12 |
mouse |